Academic Journal
The Impact of Tiered-Pricing Framework on Generic Entry in Canada
| العنوان: | The Impact of Tiered-Pricing Framework on Generic Entry in Canada |
|---|---|
| المؤلفون: | Wei Zhang, Huiying Sun, Daphne P. Guh, Larry D. Lynd, Aidan Hollis, Paul Grootendorst, Aslam H. Anis |
| المصدر: | International Journal of Health Policy and Management, Vol 11, Iss 6, Pp 768-776 (2022) |
| بيانات النشر: | Kerman University of Medical Sciences, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Public aspects of medicine |
| مصطلحات موضوعية: | tiered-pricing framework, price-cap regulation, generic drug, generic entry, canada, Public aspects of medicine, RA1-1270 |
| الوصف: | BackgroundGeneric drug prices have been capped at specified percentages of the interchangeable branded drug’s price by the Canadian provincial public drug plans since 1993. The Pan-Canadian Pharmaceutical Alliance, formed as a coalition by the provinces/territories in Canada, implemented an alternative approach, a tiered-pricing framework (TPF) for new generic drugs on April 1, 2014, under which the percentage varies with the number of generic firms in each market. We evaluate the impact of the TPF on generic entry, ie, listing in public drug plans in Canada. MethodsOur study compared the pre-TPF period (01/01/2012-03/31/2014) with the TPF period (04/01/2014-06/30/2016). Prescription drugs from nine provincial public drug plans were grouped into a “market” if they had the same active ingredient and strength, route of administration, and dosage form. Each “market” was contestable by generics and met the eligibility criteria for TPF. At the “market” level, Cox proportional-hazards models with time-varying covariates were used to measure the impact of the TPF on the first generic listing in any provincial public drug plan in Canada relative to the first launch date worldwide. ResultsA total of 189 markets in Canada were selected for the analyses. Generic drugs in small markets were more likely to be listed in Canada during the TPF period compared to the pre-TPF period (hazard ratio [HR], 95% CI: 3.81, 1.51-9.62). There was no significant difference in generic drug listings in large markets between the two policy periods. ConclusionTPF speeds up generic entry in small markets and generates the benefits of generic competition while avoiding the pitfalls of the previously employed price-cap regulations. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2322-5939 |
| Relation: | https://www.ijhpm.com/article_3955_b01a132dfdd4a6bc98e3dc17bc86efb9.pdf; https://doaj.org/toc/2322-5939 |
| DOI: | 10.34172/ijhpm.2020.215 |
| URL الوصول: | https://doaj.org/article/dd6868a591a248508fa2626b82a10b56 |
| رقم الانضمام: | edsdoj.6868a591a248508fa2626b82a10b56 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.6868a591a248508fa2626b82a10b56 972 3 Academic Journal academicJournal 972.114501953125 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.6868a591a248508fa2626b82a10b56&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/dd6868a591a248508fa2626b82a10b56 [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=23225939&ISBN=&volume=11&issue=6&date=20220601&spage=768&pages=768-776&title=International Journal of Health Policy and Management&atitle=The%20Impact%20of%20Tiered-Pricing%20Framework%20on%20Generic%20Entry%20in%20Canada&id=DOI:10.34172/ijhpm.2020.215 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => The Impact of Tiered-Pricing Framework on Generic Entry in Canada
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Wei+Zhang%22">Wei Zhang</searchLink><br /><searchLink fieldCode="AR" term="%22Huiying+Sun%22">Huiying Sun</searchLink><br /><searchLink fieldCode="AR" term="%22Daphne+P%2E+Guh%22">Daphne P. Guh</searchLink><br /><searchLink fieldCode="AR" term="%22Larry+D%2E+Lynd%22">Larry D. Lynd</searchLink><br /><searchLink fieldCode="AR" term="%22Aidan+Hollis%22">Aidan Hollis</searchLink><br /><searchLink fieldCode="AR" term="%22Paul+Grootendorst%22">Paul Grootendorst</searchLink><br /><searchLink fieldCode="AR" term="%22Aslam+H%2E+Anis%22">Aslam H. Anis</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => International Journal of Health Policy and Management, Vol 11, Iss 6, Pp 768-776 (2022) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Kerman University of Medical Sciences, 2022. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Public aspects of medicine ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22tiered-pricing+framework%22">tiered-pricing framework</searchLink><br /><searchLink fieldCode="DE" term="%22price-cap+regulation%22">price-cap regulation</searchLink><br /><searchLink fieldCode="DE" term="%22generic+drug%22">generic drug</searchLink><br /><searchLink fieldCode="DE" term="%22generic+entry%22">generic entry</searchLink><br /><searchLink fieldCode="DE" term="%22canada%22">canada</searchLink><br /><searchLink fieldCode="DE" term="%22Public+aspects+of+medicine%22">Public aspects of medicine</searchLink><br /><searchLink fieldCode="DE" term="%22RA1-1270%22">RA1-1270</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => BackgroundGeneric drug prices have been capped at specified percentages of the interchangeable branded drug’s price by the Canadian provincial public drug plans since 1993. The Pan-Canadian Pharmaceutical Alliance, formed as a coalition by the provinces/territories in Canada, implemented an alternative approach, a tiered-pricing framework (TPF) for new generic drugs on April 1, 2014, under which the percentage varies with the number of generic firms in each market. We evaluate the impact of the TPF on generic entry, ie, listing in public drug plans in Canada. MethodsOur study compared the pre-TPF period (01/01/2012-03/31/2014) with the TPF period (04/01/2014-06/30/2016). Prescription drugs from nine provincial public drug plans were grouped into a “market” if they had the same active ingredient and strength, route of administration, and dosage form. Each “market” was contestable by generics and met the eligibility criteria for TPF. At the “market” level, Cox proportional-hazards models with time-varying covariates were used to measure the impact of the TPF on the first generic listing in any provincial public drug plan in Canada relative to the first launch date worldwide. ResultsA total of 189 markets in Canada were selected for the analyses. Generic drugs in small markets were more likely to be listed in Canada during the TPF period compared to the pre-TPF period (hazard ratio [HR], 95% CI: 3.81, 1.51-9.62). There was no significant difference in generic drug listings in large markets between the two policy periods. ConclusionTPF speeds up generic entry in small markets and generates the benefits of generic competition while avoiding the pitfalls of the previously employed price-cap regulations. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2322-5939 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.ijhpm.com/article_3955_b01a132dfdd4a6bc98e3dc17bc86efb9.pdf; https://doaj.org/toc/2322-5939 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.34172/ijhpm.2020.215 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/dd6868a591a248508fa2626b82a10b56" linkWindow="_blank">https://doaj.org/article/dd6868a591a248508fa2626b82a10b56</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.6868a591a248508fa2626b82a10b56 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.34172/ijhpm.2020.215
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 9
[StartPage] => 768
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => tiered-pricing framework
[Type] => general
)
[1] => Array
(
[SubjectFull] => price-cap regulation
[Type] => general
)
[2] => Array
(
[SubjectFull] => generic drug
[Type] => general
)
[3] => Array
(
[SubjectFull] => generic entry
[Type] => general
)
[4] => Array
(
[SubjectFull] => canada
[Type] => general
)
[5] => Array
(
[SubjectFull] => Public aspects of medicine
[Type] => general
)
[6] => Array
(
[SubjectFull] => RA1-1270
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => The Impact of Tiered-Pricing Framework on Generic Entry in Canada
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wei Zhang
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Huiying Sun
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Daphne P. Guh
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Larry D. Lynd
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aidan Hollis
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paul Grootendorst
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aslam H. Anis
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 06
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 23225939
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 11
)
[1] => Array
(
[Type] => issue
[Value] => 6
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => International Journal of Health Policy and Management
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |